Skip to content
MARKETS / NASDAQ / GNLX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Genelux Corp. GNLX

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$8,000
▲ 0.0% YoY
$-32.1M
$-26.4M
In brief

What this company does

Our lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. The company has a facility in San Diego, California for current Good Manufacturing Practice (cGMP) manufacturing. In September 2021, the company entered into a License Agreement (the Newsoara License Agreement) with Newsoara BioPharma Co. Ltd. Genelux Corporation was incorporated in Delaware in September 2001. The Company completed its initial public offering (IPO) in January 2023, and its common stock is listed on the Nasdaq Capital Market under the symbol “GNLX.”

Written from the business description in Genelux Corporation's annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth
USD 8,000.00
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -32.1
4M8M-20M2022202320242025
Compound annual growth
−91.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−401812 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -415175.0% · Net -401812.5%
-200000%-400000%2022202320242025
ROE
FY2025 · ROE -170.0%
-50%-100%-150%2022202320242025
Gross margin
Operating margin-415175.0%
Net margin-401812.5%
Return on assets-119.6%
EBITDAUSD -33.0M

Each USD of equity lost 170 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -26.4
-10M-20M2022202320242025

Total assetsUSD 19.0M
EquityUSD 11.5M
CashUSD 5.3M
Current ratio2.43×

Equity funds 61% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0
Income tax $B···0.0
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0
EPS, diluted $−0.86−0.95−1.16−0.57
Dividend / sh $····
Payout %····
ROE %−170.0−130.6··
Shares out B0.040.030.030.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 16 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2022

Share this section

Download image